News
PBYI
6.90
+2.07%
0.14
Puma Biotechnology grants inducement RSUs covering 31,625 shares to five new employees
Reuters · 1d ago
PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 1d ago
Weekly Report: what happened at PBYI last week (0323-0327)?
Weekly Report · 4d ago
Weekly Report: what happened at PBYI last week (0316-0320)?
Weekly Report · 03/23 09:04
Weekly Report: what happened at PBYI last week (0309-0313)?
Weekly Report · 03/16 09:04
Weekly Report: what happened at PBYI last week (0302-0306)?
Weekly Report · 03/09 09:04
Weekly Report: what happened at PBYI last week (0223-0227)?
Weekly Report · 03/02 09:04
Puma Biotechnology Balances Growth, Trials and Profitability
TipRanks · 03/02 00:08
Puma Biotechnology (PBYI) Margin Resilience Tests Bearish Earnings Forecasts In FY 2025 Results
Simply Wall St · 02/28 02:30
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 02/27 17:05
Analysts Are Neutral on Top Healthcare Stocks: Puma Biotechnology (PBYI), Cytek Biosciences (CTKB)
TipRanks · 02/27 04:50
Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
Seeking Alpha · 02/27 02:38
UPDATE: Puma Biotechnology Sees FY2026 Sales $214.000M-$221.000M vs $220.000M Est
Benzinga · 02/26 23:58
UPDATE: Puma Biotechnology Q4 Adj. EPS $0.29 Beats $0.23 Estimate, Sales $75.500M Beat $68.600M Estimate
Benzinga · 02/26 23:09
Puma Biotech (PBYI) Earnings Call Transcript
The Motley Fool · 02/26 22:53
Puma Biotechnology reports Q4 EPS 26c vs. 39c last year
TipRanks · 02/26 22:00
Puma Biotechnology sees Q1 revenue $38M-$42M, one estimate $49M
TipRanks · 02/26 21:59
Puma Biotechnology Q4 product revenue rises to $59.9 mln
Reuters · 02/26 21:57
Puma Biotechnology Non-GAAP EPS of $0.29 beats by $0.06, revenue of $75.5M beats by $6.9M
Seeking Alpha · 02/26 21:39
Puma posts Q4 royalty revenue up 3.3x to USD 15.6 million
Reuters · 02/26 21:08
More
Webull provides a variety of real-time PBYI stock news. You can receive the latest news about Puma Biotechnology Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.